Skip to main content

Table 2 Clinical characteristics by history of calcinosis

From: Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis

Risk factor Descriptive analysis    Univariable analysis
Calcinosis   OR [95% CI] p-value
Yes No
Gender n (%) 0.0138   
 Male 33 (39.3) 144 (26.3)   1.811 [1.123–2.919] 0.0148
 Female 51 (60.7) 403 (73.7)    
Age (years) median (IQR)    
 At symptom onset 6 (4.2–9) 5.5 (3.6–9.3)    
 At diagnosis 8 (5.4–10.6) 6.3 (4.2–9.8) 0.0424   
 Time to diagnosis (months) 8.8 (2–23.6) 3.8 (1.9–8.9) 0.0011 1.029 [1.016–1.043] < 0.0001
Ethnicity n (%)    
 Hispanic 12 (14.3) 83 (15.2)    
Race    0.0047   
 Caucasian 61 (72.6) 458 (83.7)    
 African-American 19 (22.6) 63 (11.5)   2.264 [1.270–4.038] 0.0056
 Missing 4 (4.8) 26 (4.8)    
JDM Category n (%)    
 Amyopathic 2 (2.4) 7 (1.3)    
 Probable 61 (72.6) 429 (78.4)    
 Definite 8 (9.5) 40 (7.3)    
 Missing 13 (15.5) 71 (13)    
Clinical features n (%)    
 Lipodystrophy 11 (13.1) 13 (2.4) < 0.0001 5.993 [2.588–13.874] < 0.0001
 Joint contractures 23 (27.4) 35 (6.4) < 0.0001 5.343 [2.964–9.635] < 0.0001
 Cutaneous ulceration 12 (13.5) 23 (4.2) 0.001 3.748 [1.787–7.862] 0.0005
 Gottron’s or Heliotrope 50 (59.5) 244 (44.6) 0.0176 1.754 [1.099–2.800] 0.0186
 Dysphagia or dysphonia 26 (31) 107 (19.6) 0.0178   
 Small joint arthritis 25 (29.8) 115 (21.0) 0.041   
 Malar or facial erythema 31 (36.9) 182 (33.3)    
 V or Shawl sign 9 (10.7) 25 (4.6) 0.0377 2.410 [1.083–5.361] 0.0311
 Periungal Telangiectasia 40 (47.6) 225 (41.1)    
 Cardiac involvement 4 (4.8) 10 (1.8)    
 Gastrointestinal ulceration 3 (3.6) 7 (1.3)    
 Interstitial lung disease 4 (4.8) 11 (2.0)    
 Any organ involvementa 9 (10.7) 25 (4.6) 0.0333 2.506 [1.127–5.573] 0.0243
 Large joint arthritis 26 (31) 147 (26.9)    
 Muscle enzyme elevation 74 (88.1) 481 (87.9)    
 Severe muscle weakness 2 (2.4) 14 (2.6)    
  1. aComposite outcome: includes cardiac, GI or lung involvement